Benedikt Pulver

Benedikt Pulver

Auto-generated profile, based on publicly available information

Benedikt Pulver

Forensic Toxicology, Institute for Legal Medicine, Medical Center, Faculty of Medicine, University of Freiburg, University of Freiburg, Freiburg, Germany

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 November 2022 in Drug Testing and Analysis
Verified
Journal Article
Closed access
BPBenedikt Pulver
Benedikt Pulver
SFSvenja Fischmann
Svenja Fischmann
AGAna Gallegos
Ana Gallegos
RCRachel Christie
Rachel Christie

27 April 2021 in Drug Testing and Analysis
Verified
Journal Article
Open access
PDF file
KGKatharina Elisabeth Grafinger
Katharina Elisabeth Grafinger
MVMarthe M. Vandeputte
Marthe M. Vandeputte
ACAnnelies Cannaert
Annelies Cannaert
AAAdam Ametovski
Adam Ametovski
ESEric Sparkes
Eric Sparkes
Volker AuwärterVolker Auwärter
Volker Auwärter
The present work is the last of a three‐part study investigating a panel of 30 systematically designed synthetic cannabinoid receptor agonists (SCRAs) including features such as the 4‐pentenyl tail and varying head groups including amides and esters of l‐valine (MMB, AB), l‐tert‐leucine (ADB), and l‐phenylalanine (APP), as well as adamantyl (A) and cumyl moieties (CUMYL). Here, we evaluated these SCRAs for their capacity to activate the human cannabinoid receptor 1 (CB1) via indirect measurement of G protein recruitment. Furthermore, we comparatively evaluated the results obtained from three in vitro assays, based on the recruitment of β‐arrestin 2 (βarr2 assay) or Gαi protein (mini‐Gαi assay), or binding of [35S]‐GTPγS. The observed efficacies (Emax) varied depending on the conducted assay. Statistical analysis suggests that the population means of the relative intrinsic activity (RAi) significantly differ for the [35S]‐GTPγS assay and the other two assays, but the population means of the βarr2 and mini‐Gαi assays were not statistically different. Our data suggest that differences observed between the βarr2 and mini‐Gαi assays are the best predictor for ‘biased agonism’ towards βarr or G protein recruitment in our study. SCRAs carrying an ADB or MPP moiety as a head group tended to produce elevated Emax values in the βarr2 assay, which might result in a tendency of these compounds to cause pronounced tolerance in users—a hypothesis that should be evaluated further by future studies. In general, a comparison of efficacies derived from different assays is difficult and should only be conducted very cautiously.

10 October 2020 in Drug Testing and Analysis
Verified
Journal Article
Open access
PDF file
SHSebastian Halter
Sebastian Halter
BPBenedikt Pulver
Benedikt Pulver
MWMaurice Wilde
Maurice Wilde
BHBelal Haschimi
Belal Haschimi
FWFolker Westphal
Folker Westphal
Volker AuwärterVolker Auwärter
Volker Auwärter
Since the beginning of the phenomenon of new psychoactive substances (NPS), synthetic cannabinoid receptor agonists (SCRAs) have been the largest and most prevalent subclass of these drugs in Europe. Many countries implemented specific legislation scheduling classes of substances defined on the basis of their chemical structure to reduce supply. We describe the identification and analytical characterization within the EU project ADEBAR plus of 1‐(cyclobutylmethyl)‐N‐(2‐phenylpropan‐2‐yl)‐1H‐indole‐3‐carboxamide which resulted in the formal notification through the Early Warning System of the European Monitoring Centre for Drug and Drug Addiction (EMCDDA). This is the first identification of this new SCRA worldwide and the analytical data was distributed (inter‐)nationally right after identification in 2019. First, the substance was isolated from the herbal material using preparative high‐performance liquid chromatography (HPLC). Structure elucidation and analytical characterization were performed using gas chromatography–mass spectrometry (GC–MS), gas chromatography‐solid state infrared spectroscopy (GC‐sIR), liquid chromatography‐electrospray ionization‐quadrupole time of flight‐mass spectrometry (LC‐ESI‐qToF‐MS), Raman spectroscopy, and nuclear magnetic resonance (NMR) spectroscopy. The new compound contains a cyclobutyl methyl group as a side chain and has not been described in any patent to our knowledge. Based on the semisystematic nomenclature of SCRAs, we propose Cumyl‐CBMICA as a short name for the compound.

8 December 2021 in Drug Testing and Analysis
Verified
Journal Article
Closed access
PDF file
SBSimon Brandt
Simon Brandt
PKPierce V. Kavanagh
Pierce V. Kavanagh
FWFolker Westphal
Folker Westphal
BPBenedikt Pulver
Benedikt Pulver
KMKathleen Morton
Kathleen Morton
AHAdam L. Halberstadt
Adam L. Halberstadt

24 May 2022 in Drug Testing and Analysis
Verified
Journal Article
Open access
BPBenedikt Pulver
Benedikt Pulver
SFSvenja Fischmann
Svenja Fischmann
FWFolker Westphal
Folker Westphal
TSTorsten Schönberger
Torsten Schönberger
JSJan Schäper
Jan Schäper
MPMichael Pütz
Michael Pütz
Novel substances for which none or limited analytical data are available constitute a challenge for police and customs forensic laboratories. The time‐consuming process of structural elucidation and acquisition of analytical data has been centralized in the ADEBAR project in Germany, co‐funded since 2017 by the EU's Internal Security Fund. The project aims to comprehensively characterize substances relevant for forensic‐toxicological casework within the analytical competence network. The analytical datasets are distributed digitally through European and (inter)national channels. Additionally, pharmacological evaluation allows for estimating in vivo potency and potential harm required as scientific evidence for legislative amendments. The ADEBAR project contributes to the availability of analytical data on new substances relevant to the daily work of police and customs laboratories. Since the inception of the ADEBAR project, 549 samples have been registered, and 302 substance reports notified to the EMCDDA, including numerous spectrometric and spectroscopic data. In addition, 3,619 mass spectra have been accumulated in ADEBAR mass spectra databases. A central institution for the structure elucidation and acquisition of valid, high‐quality analytical data for police and customs forensic laboratories and forensic medicine institutes is important in the future because there does not seem to be an end to the dynamic of novel NPS appearing on the drug market.

29 May 2022 in Drug Testing and Analysis
Verified
Journal Article
Open access
SBSimon Brandt
Simon Brandt
PKPierce V. Kavanagh
Pierce V. Kavanagh
FWFolker Westphal
Folker Westphal
BPBenedikt Pulver
Benedikt Pulver
HSHannes M. Schwelm
Hannes M. Schwelm
AHAdam L. Halberstadt
Adam L. Halberstadt
Lysergic acid diethylamide (LSD) is known to induce powerful psychoactive effects in humans, which cemented its status as an important tool for clinical research. A range of analogues and derivatives has been investigated over the years, including those classified as new psychoactive substances. This study presents the characterization of the novel lysergamide N,N‐diethyl‐1‐propanoyl‐6‐(prop‐2‐en‐1‐yl)‐9,10‐didehydroergoline‐8β‐carboxamide (1P‐AL‐LAD) using various mass spectrometric, gas‐ and liquid chromatographic and spectroscopic methods. In vitro metabolism studies using pooled human liver microsomes (pHLM) confirmed that 1P‐AL‐LAD converted to AL‐LAD as the most abundant metabolite consistent with the hypothesis that 1P‐AL‐LAD may act as a prodrug. Fourteen metabolites were detected in total; metabolic reactions included hydroxylation of the core lysergamide ring structure or the N6‐allyl group, formation of dihydrodiol metabolites, N‐dealkylation, N1‐deacylation, dehydrogenation, and combinations thereof. The in vivo behavioral activity of 1P‐AL‐LAD was evaluated using the mouse head twitch response (HTR), a 5‐HT2A‐mediated head movement that serves as a behavioral proxy in rodents for human hallucinogenic effects. 1P‐AL‐LAD induced a dose‐dependent increase in HTR counts with an inverted U‐shaped dose–response function, similar to lysergic acid diethylamide (LSD), psilocybin, and other psychedelics. Following intraperitoneal injection, the median effective dose (ED50) for 1P‐AL‐LAD was 491 nmol/kg, making it almost three times less potent than AL‐LAD (174.9 nmol/kg). Previous studies have shown that N1‐substitution disrupts the ability of lysergamides to activate the 5‐HT2A receptor; based on the in vitro metabolism data, 1P‐AL‐LAD may induce the HTR because it acts as a prodrug and is metabolized to AL‐LAD after administration to mice.